The consensus is that TCPTC is related to aggressive clinicopathological parameters, including tumor stage, tumor multifocality, extrathyroidal extension, lymphovascular invasion, initial lymph node metastasis, pre-ablation lung metastasis, and BRAF mutations.[1,5,6,9–11] However, studies on the outcomes of patients with TCPTC have revealed controversial results.[5,7,11,12] Although numerous studies that have investigated the biological characteristics of TCPTC,[13,14] the molecular mechanisms underlying TCPTC remain poorly understood. Here, BRAF is linked to neoplasm.